Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Investment analysts at Leerink Partnrs issued their FY2028 earnings estimates for shares of Relmada Therapeutics in a research report issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of ($0.90) per share for the year. The consensus estimate for Relmada Therapeutics' current full-year earnings is ($3.33) per share.
https://www.marketbeat.com/instant-alerts/nasdaq-rlmd-analyst-earnings-estimates-2024-01-30/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.